Life Sciences Archive » March, 2024

Life Sciences - March, 2024

285 articles

• Petition Watch: Off-Label Ads, Retiree Discrimination & PPE
• Northern Texas Judges Won't Adopt Judge-Shopping Rule
• Hogan Lovells Vet's High Court Debut A Study In Contrasts
• Alleged 'Shadow Trader's Co-Worker Tells Jury Stocks Not Tied
• Judge Denies Injunction For Tyvaso Drug Competitor
• Fed. Circ. Tears Cancer Testing Rivals Apart In Injunction Args
• SEC Wins Extended Asset Freeze Against Biotech Co.
• Allergan Scoffs At Sandoz Bid To Undo $39M Patent Loss
• Judge Axes UpHealth's Claim Estimation Bid In Bankruptcy
• Hedge Fund Beats Vaxart Investor's 'Short-Swing' Profits Suit
• Del. Judge Clears Liquidia To Sell Lung-Disease Drug
• THL's $2.5B Deal To Buy Agiliti Sparks Chancery Suit
• NJ Law Firm Can Keep Benicar Malpractice Suit In Fed. Court
• Exec Says Pharma Co. Yanked Job Offer Over ADHD Medication
• Biotech Co. Inflated Gene Therapy Prospects, Investors Claim
• Stay Interviews Are Key To Retaining Legal Talent
• Penile Implant Doc Awarded $18.3M After Trade Secrets Trial
• Accused 'Shadow Trader' Can't Recall Why He Bought Stock
• Fed. Circ. Won't Stop Sales Of Heart Valve Testers
• 2 Firms Steer Close Of Hildred's $750M Continuation Fund
• Pfizer Wants Moderna Vax IP Case Paused For PTAB Review
• Fees Awarded For 'Feeble' Milk Vitamin Eligibility Argument
• Rite Aid Says It Has Creditor Deal, Gets OK For Plan Vote
• Direct Claims Ruling May Alter Gov't Ties To Software Firms
• MSG-Maker Says Chinese Exporters Skirting Duties Via Malaysia
• Implant Maker's Bribe Case Ripe For Trimming, Judge Says
• Intoxicating Hemp Products: It's High Time For Clarity
• McCarter & English Wins Extra $1.8M In Client Billing Suit
• Merger News Boosts Rivals, 'Shadow Trading' Jury Told
• Latham, Cooley Steer Oncology Firm's $100M IPO
• ITC Judge Recommends Exclusion Order In Tourniquet IP Row
• NY AG, Others Blast Sandoz Deal 'Tax' On Future Settlements
• And Now A Word From The Panel: Benefits Of MDL Transfers
• What Rescheduling Could Mean For Cannabis Bankruptcies
• Eli Lilly Age Bias Suit Over Promotions Nabs Collective Status
• BCBS Can't Escape Therapy Coverage Suit
• Jackson Paints Abortion Clash As Microcosm Of Bigger Brawl
• Banker Describes Confidential Work In 'Shadow Trading' Trial
• Pharmacy Owner Gets 42 Months For $25M Kickback Scam
• FTC Urges Court To Pause Novant's NC Hospital Deal
• Opioid Public Nuisance Claims 'Unique,' Ohio High Court Told
• Pharmacies Need More Protection Against PBM Fee Practices
• Contract Disputes Recap: Facts Differ But Same Rules Apply
• In Abortion Case, Gorsuch Frets 'Rash' Of National Injunctions
• 6 Firms Build $340M SPAC Merger For AI-Driven Medicine Biz
• Pet Drug Maker Faces EU Probe For Axing Pipeline Dog Med
• High Court Wary Of Bid To Limit Abortion Pill Access
• Spray Painting Makes Me A Better Lawyer
• SEC Kicks Off 'Shadow Trading' Case Against Drug Exec
• COVID 'Cure' Claims Can't Sustain Fraud Suit, 9th Circ. Rules
• J&J Exec 'Shocked' Over Atty's Ties With Talc Plaintiffs
• Amgen Sues Colorado After Drug's 'Unaffordable' Rating
• PacBio CEO's Words Haunt Patent Invalidity Arguments
• PTAB Splits On Medtronic Bladder And Bowel Control Patents
• What To Watch As Opioid Litigation Goes To Ohio High Court
• Fed. Circ. Dissent Raises Alarm Over IP Safe Harbor Use
• FTC Intervenes In Teva-Amneal Row To Push Patent Delisting
• Fla. Pharmacy Says It Was Cut From Federal PrEP Program
• Pilot For UK Billionaire Says Stock Tips Case Is Too Vague
• Takeaways From The 2023 DOJ Fraud Section Report
• Paul Weiss-Led AbbVie Inks Up To $212M Deal For Landos Bio
• Judge-Shopping Policy Revisal May Make Issue Worse
• 3rd Circ. Won't Rethink AbbVie Privilege Ruling
• 2nd Circ. Baby Food Ruling Disregards FDA's Expertise
• Catching Up With Delaware's Chancery Court
• Novo Nordisk Inks $1.1B Deal For German Pharma Biz
• Kirkland Guides Ingersoll Rand On $2.3B ILC Dover Buy
• Gilead's Win Upheld In Billion-Dollar HIV Drug Patent Case
• Jury Says Dexcom Infringed 1 Abbott Patent In Mixed Verdict
• Robitussin Buyers' Lack Of Receipts Dooms Labeling Cert.
• Expert's Sanctions Off Limits In SEC's 'Shadow Trading' Trial
• Pharma Co. Brass Overhyped ALS Drug Efficacy, Suit Says
• Up Next At High Court: Abortion, Jury Trials And Estate Tax
• Md. University Says Psilocybin Trade Theft Suit Belongs In US
• $900M Trade Secrets Case Against Kaiser Foundation Flops
• Final OK Sought For Economic Loss Deal In CPAP Recall MDL
• Radiology Co., Trustee Must Face Ex-Worker's ESOP Suit
• Vanda's Obviousness Appeal Isn't Worthwhile, Teva Tells Justices
• High Court Mifepristone Battle Goes Beyond Abortion
• Ex-Drug Rep Won't Serve More Time After 1st Circ. Victory
• NJ Appeals Court Shuts Down Fired White Worker's Bias Suit
• US Greenlights Novartis' $2.9B MorphoSys Takeover
• UK Litigation Roundup: Here's What You Missed In London
• 87-Year-Old Billionaire Lewis Seeks No Jail For Insider Trading
• Del. Courts Examining 'Colonoscopy'-Like Bylaw Rules
• LifeCell Cleared Of Liability In NJ Strattice Hernia Mesh Trial
• SEC's 'Shadow Trading' Trial To Test Insider Info Boundaries
• Colo. Distributor Seeks $2.3M Sanction For Stryker Spoilation
• Schumer Urges Texas District To Adopt Judge-Shopping Rule
• Ill. Judge Leaves Outcome Health Execs' Convictions Intact
• MDL Claims Over Merck's Gardasil Vax Get Trimmed
• 6th Circ. Revives McKee's Network Plan Fight With Thrifty Med
• Calif. Panel Revives Diner's COVID Sanitization Coverage Bid
• Tribe's Opioid Suit Can Head To State Court, Okla. Judge Says
• CymaBay Investor Sues For Books On $4.3B Gilead Merger
• Avoid Major Extension Of Merger Reach, EU High Court Urged
• Business Coalition Rebuffs Biden Plan To Seize Drug Patents
• Home Health Cos. Stiffed Workers On OT Pay, Suit Claims
• Assessing FDA Pathways For Genome-Edited Plant Foods
• Teleflex Catheter Patent Makes It Through Fed. Circ.
• Woman Lost Independence Due To Strattice Mesh, Jurors Told
• 3rd Circ. Agrees Investors Have No Case Against Vax Maker
• Proposed MDL Management Rule Needs Refining
• 6th Circ. Doubtful Of Hospital Workers' Vax Exemption Claim
• Why Oncology Deal Making Continues To Fuel Biotech M&A
• Fed. Circ. Upholds Edwards' PTAB Win On Heart Valve Patent
• 6th Circ. Zeroes In On CBA In Vax Bias Preemption Battle
• Chancery Denies Icahn Midcase Appeal In Illumina Board Suit
• Greenberg Traurig Adds Jackson Walker FDA Pro In Houston
• Judicial Independence Is Imperative This Election Year
• 4th Circ. Backs Rockefeller Group in Guatemalans' Syphilis Suit
• Endo Plan To Trim $5B In Debt Confirmed By NY Judge
• NIST March-In Framework Is As Problematic As 2021 Proposal
• PTAB To Analyze Moderna COVID Vaccine Patents
• Jenner & Block-Led Lonza To Buy Roche's $1.2B US Facility
• Digital Comms Filings Bolster Record EPO Applications
• Document Retention Best Practices To Lower Litigation Risks
• Int'l Olympic Committee Rips Russia For Politicizing Sports
• Top Attorney For Bristol-Myers Squibb Earned $5.9M In '23
• Riding My Peloton Bike Makes Me A Better Lawyer
• Boehringer Wins Diabetes Treatment Patent On Appeal In EU
• How The Supreme Court Could Narrow Chevron
• 2 Biotechs Unveil Separate Fundings Totaling $325M
• Law360 Announces The Members Of Its 2024 Editorial Boards
• US Chamber's Litigation Funding Concerns Spur 2 State Laws
• Healthcare Policy Roundup: HHS Budget, Telehealth, PBMs
• Schumer Scolds McConnell For Judge-Shopping Policy Rebuff
• Acorda Says Tribunal Ignored Patent Law In MS Drug Feud
• Law Firm Hit With Suit Over Abandoned Patent Application
• Ala. Frozen Embryo Ruling Creates Risks for Managed Care Orgs
• NBA Fraudster Dodges Prison After Cooperation, Testimony
• Skin Care Drug Co. Can Ask Creditors To OK Ch. 11 Plan
• Cancer Patient Fights Monsanto's Philadelphia Roundup Win
• Future Of Judge-Shopping Reform Hazy After Rule Proposal
• OptumRx Can't Get Motley Rice Disqualified From Opioid MDL
• IFF Selling Pharma Unit To French Co. Roquette In $2.85B Deal
• Spartan Arbitration Tactics Against Well-Funded Opponents
• Patent Suit Over AstraZeneca's Tagrisso Heads To Jury
• 2nd Circ. Rejects 'New Standard' Of Patent Monopolies
• 4th Circ. Sends Opioid 'Nuisance' Question To W.Va. Top Court
• Conn. Pharmacy, FDA Say They've Settled Suit Over Probe
• Biotech Ardelyx Beats Shareholder Suit Over Kidney Drug
• High Court Doubts Feds Coerced Social Media Cos.
• Kimberly-Clark Gets OK For $6M Deal Over Tainted Wipes
• Leerink Enticed Goldman Exec With False Promises, Suit Says
• Uncertainty Surrounds Patent Eligibility Restoration Bill
• ​​​​​​​Amyris Gets OK To Settle Pot Co.'s $15M Trade Secret Suit
• Catching Up With Delaware's Chancery Court
• Pfizer To Reduce Stake In Haleon To 24% Through Share Sale
• Up Next At High Court: Gov't Jawboning & Retaliatory Arrests
• Judiciary Clarifies Judge Shopping Policy After Senator Letter
• 8th Circ. Nixes Arbitration Bid In $9M Chinese PPE Fight
• 'Cobra Venom' Painkiller Co. Inks Deal To Settle SEC Claims
• CSA Case Could Shift Intrastate Commercial Cannabis
• Enfamil Maker Hit With $60M Jury Verdict In Infant Death Suit
• Hospitals Say Constitutional Defenses Valid In FTC Merger Row
• How AI May Be Used In Fintech Fraud — And Fraud Detection
• Ex-Fugitive Behind Fake Silver COVID Cure Pleads Guilty
• Conservative Law Group Asks Justices To Hear FDA Vape Suit
• What Recent Study Shows About AI's Promise For Legal Tasks
• Pharma Co. Misled Investors On Research Methods, Suit Says
• Deals Rumor Mill: Trump-Musk, Icahn-Illumina, Paramount
• Feds Seek 20 Mos. For Aegerion Fraud 'Puppet Master'
• Drug Wholesalers Want Preliminary OK On $265M Sandoz Deal
• Trial Challenging NC Abortion Restrictions Pushed To July
• EPA Slashes Ethylene Oxide Emissions Levels For Sterilizers
• 9th Circ. Unsure If Abortion Pill Suit Harms Red States
• Pharma Co. CEO Partly Beats Investor Suit Over Kidney Drug
• HHS To Investigate Whether Cyberattack Exposed Patient Data
• Planned Parenthood Foe Calls Immunity Claim 'Half-Baked'
• Aetna Can't Avoid Bias Suit Over Fertility Treatment Policy
• Jury Must Weigh Willfulness In Secrets Case, Calif. Court Says
• BigLaw Paper Poacher Gets 15 Mos. In Merck Insider Case
• Fed. Circ. Patent Lesson: No Contradiction, No Indefiniteness
• Eli Lilly GC's Pay Jumped To $7M In 2023 Amid Stock Boom
• Daiichi Urges Court To OK Arbitrator's Award Against Seagan
• Federal Circuit Won't Reconsider Axing Tyvaso Patent
• Judiciary Touts New Policy To Rein In Judge Shopping
• NY Jury Rules Some Claims About Prevagen Are Misleading
• 2nd Circ. Revives Parts Of McKesson Whistleblower Suit
• Breast Implant Co.'s $90M DIP OK'd With Creditor Protections
• Ex-Biopharma CEO Sues For Post-Sale Share Appraisal In Del.
• Sorrento Ch. 11 Will Stay In Texas
• Reps Push Regulators For Answers On Marijuana Research
• 11th Circ. FMLA Ruling Deepens Divide Over Causation
• Decline In Same-Industry M&A Tells A Nuanced Policy Story
• Nurses' Challenge To NJ Vaccine Mandate Moot, Judge Rules
• Pharmacy Calls $11M False Claims Case A 'House Of Cards'
• Paul Weiss' Digital Tech Chair On AI's Promises And Perils
• Insider Trader Cites 'Carelessness' Of BigLaw Ex-Girlfriend
• Acadia Investors Get Class Cert. In Suit Over Parkinson's Drug
• Illumina Brass Faces Shareholder Suit Over Grail Deal Debacle
• 3rd Circ. Finds No Reason To Disturb AbbVie Privilege Ruling
• Judge OKs Eye Care Tech Co.'s $8M DIP Request
• Fed. Circ. OKs Boston Drug Developer's Patent Win
• Pfizer Slams Ex-Compliance Officer's Whistleblower Claims
• What's At Play In Rising Lanham Act Cases At The ITC
• Walmart Fails To Sink Feds' Opioid Crisis Lawsuit
• BIPA's Statutory Exemptions Post-Healthcare Ruling
• SEC Can't Rely On 'Flawed' Ruling To Avoid Retrial, Atty Says
• Key Factors In Establishing Compelling Merits At The PTAB
• Pfizer Defeats French Group's Bid For Vax Docs At 2nd Circ.
• Catching Up With Delaware's Chancery Court
• Trump 'An Existential Threat' To Rule Of Law, Attys Warn
• Inside The Climactic Clash Over Skyrocketing MDL Caseloads
• Cahill Has 'Great Ambitions' To Take IP Litigation By Storm
• FDA Pumps Brakes On Eli Lilly Alzheimer's Drug Approval
• UK Enforcers To Appeal Nixed £100M Hydrocortisone Fine
• Colo. DNA Scientist Fudged Data For 650 Cases, Police Say
• 7th Circ. Wants 'Roadmap' For Ill. Workplace Disease Law
• Sorrento Gets OK For $2M Ch. 11 Funding Infusion, Asset Sale
• Litigation Inspiration: A Source Of Untapped Fulfillment
• Abortion, Drug Costs Top Health Issues in State Of The Union
• Petition Watch: Student Athletes, Oil Spills & Preemption
• Judges Say Facing Threats And Vitriol Now Part Of The Job
• Judge Doubts Medicare Drug Pricing Amounts To 'Taking'
• IP Forecast: 2nd Circ. To Consider Whether Seltzer Is Beer
• Harpoon Shareholder Sues For Records On $680M Merck Buy
• Sens. Tell Stores To Get Illegal E-Cigs Off Their Shelves
• What FTC's 'Killer Acquisition' Theory Means For Pharma Cos.
• Fed. Circ. Says IP License May Be Part Of Procurement Deal
• Feds Want 3 Years For Trader Who Spied BigLaw Ex's Binder
• Moses & Singer Healthcare Atty Joins Day Pitney In Hartford
• Skiing Makes Me A Better Lawyer
• Activist Caligan Sets Sights On Anika Therapeutics Again
• Top Calif. Antitrust Atty Says Criminal Cases On The Horizon
• Garland On AI Crime, And A Taylor Swift Tune For DOJ
• Juul MDL Judge Asks Feds To Probe AI Fraud In $45.5M Deal
• Pa. Pharma Co. Cops To Adulterated-Drug Charges
• CBP Details Apple Watch Redesign OK In Masimo Patent Row
• J&J Seeks Exit From Suit Over Stelara Exclusivity
• 5th Circ. Weighs 'Very Complex' Chemo Hair Loss Dispute
• PTAB Has To Rehear Challenge In Biotech Row
• The Road Ahead For Florida's Drug Importation Program
• Corporate Vet Joins Orrick's Tech Group From Wilson Sonsini
• Assessing CDC's Revised Guideline On Opioid Prescriptions
• Biopharmaceutical Biz Closes $259M Upsized Funding Round
• Challenge To Pfizer Diversity Program Fails At 2nd Circ.
• Ex-Stimwave CEO Found Guilty Of Healthcare Fraud
• Ohio Neurologist Can't Shorten His Drug Kickback Sentence
• UMass, L'Oreal Fight Over Anti-Aging Cream May Be Near End
• White House To Crack Down On Illegal, Unfair Pricing
• Fed. Circ. Upholds Axing Pfizer Vax IP But Calls For More Info
• Gibson Dunn AI Leader On Weathering The AI Policy Blizzard
• Pharmacist Takes Deal In Mich. Over Fatal Meningitis Outbreak
• Magnolia Medical Again Sues Kurin Over Sepsis IP
• CVS Again Defeats NY AG's Drug Rebate Tying Claims
• FTC Chair Decries PE's Healthcare Impacts As Probe Starts
• Avadel Told To Pay Jazz Pharma $234K Over Narcolepsy Drug IP
• Think Like A Lawyer: Forget Everything You Know About IRAC
• GOP Sens. Voice Concern Over Biden Plan To Claim Patents
• FDA Rejection Of Fosamax's Label Fix Not Final, 3rd Circ. Told
• IP Litigation Vet Joins Wiggin and Dana's NY Office From LTL
• DLA Piper Adds Merck SVP As New Life Sciences Sector Chair
• Valeant Ruling May Pave Way For Patent-Based FCA Suits
• Monsanto Nabs 1st Win In Philly's Roundup Trial Blitz
• J&J Trial Over Doctor's Cancer Death Ends In Hung Jury
• Crowell & Moring Int'l Names Global Life Sciences Head
• Elanco Urges Justices To Preserve Junk Fax Win
• WTO Conference Ends Without COVID IP Waiver Expansion
• Trial Of Ex-Stimwave CEO Over Medical Device Nears End
• Bayer Pays $310M For European Rights To Heart Drug
• French Spinal Care Co. Can't Get €4.2M Award Enforced
• Sorrento Creditors Fight To Keep Ch. 11 In Texas
• Antibe Therapeutics To Pay Nuance $24M In Licensing Fight
• Catching Up With Delaware's Chancery Court
• Gov't Says AI Patent Gap Between US And China Is Growing
• Ventyx Investor Says Co. Overhyped Psoriasis Drug
• Adamas' Ex-COO Agrees To $4.6M Deal In Investor Suit
• 3rd Circ. Preview: Exxon Whistleblower Case Fuels March
• USPTO Wants To Make Patent Amendment Pilot Official
• Blockbuster Drug Sales Help Keep J&J Patent Alive
• J&J's Talc Lit The Spark For Doctor's Fatal Cancer, Jury Told
• Cannabis Consulting Co. Says Clinic Owes $101K On Contract
• NY Judge Tosses $6.4B BMS Investor Action For Good
• 55K Labcorp 401(k) Participants Seek Class Cert. In NC
• Tort Report: $42M Med Mal Award; Hot Coffee Suit In The Air
• CVS, Walgreens Receive FDA's OK To Dispense Abortion Drug
• Suits Against Insulin Pricing Are Driven By Rebate Addiction
• Gilead, Cipla Ink Deal To End HIV Drug Buyers' Antitrust Suit
• Panel Backs Tossing Of Eli Lilly, Bayer Drug Marketing Suits
• Lessons For D&O Policyholders From Pharma Co. Ruling
• Morgan Lewis Adds Otsuka Pharmaceutical Atty In DC
• How Firms Can Ensure Associate Gender Parity Lasts
• UK Litigation Roundup: Here's What You Missed In London